SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week® (DDW). DDW is the world’s premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, and will take place in person and virtually May 21-24, 2022.
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
Globe Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
